Anavex Life Sciences Corp (AVXL)

[falconer66a]

“Preclinical Drugs Are Too Risky, Period”

With your stated trepidations, could you illustrate for us any sort of pre-clinical drug, absent definitive Phase 3 clinical trial data that you would ever recommend investing in?

Would it be accurate, then, to understand that you simply would never invest in any pharmaceutical equity that hasn’t already gained regulatory approval for sale and medical use? Until that occurs, investors such as yourself cannot know with sufficient certainty any of the various matters of a drug’s success: a) safety, b) tolerability, c) effective dosage levels, d) levels and forms of treatment efficacies, e) precise understanding of a drug’s biochemistry and mechanism of action, f) size of the drug’s market, and g) acceptability and frequency of prescription by practicing physicians (market use).

Fair to say? “Nope, unapproved drugs, without established records of treatment, are simply too speculative for retail investors to risk their equity investment funds on. Simply, stay away from investments like Anavex Life Sciences Corp. You can’t know enough about their potential drugs to be safe and secure with your hard-earned dollars.”

Pretty much sums it up, does it not?